Unlearn, a San Francisco, CA-based AI company specializing in creating digital twins of clinical trial participants to enable smaller, faster studies, raised $50 million in Series C funding.
The round was led by Altimeter Capital, joined by returning investors Radical Ventures, Wittington Ventures, Mubadala Capital, Epic Ventures, and Necessary Venture Capital.
Founded in 2008, Altimeter Capital Management is a venture capital firm based in Menlo Park, California. The firm prefers to invest in information technology and B2C restaurants. The firm employs long-, short-, and fundamental strategies for equity investment.
Unlearn Use of Funds
The funding will propel Unlearn's mission to advance AI to eliminate trial and error in medicine. The funds will be used to invest in people, data, engineering capabilities, and longer-term R&D initiatives.
Founded in 2017, Unlearn is a technology company advancing AI to eliminate trial and error in medicine. Its AI models generate individual digital twins for every trial participant before randomization into the experimental or control arm. These digital twins forecast health outcomes under a placebo, regardless of the actual assignment. Unlearn's technology powers the clinical trials of leading global pharmaceutical companies, helping them to reach full enrollment faster and bring new treatments to patients sooner. Their methods using participants’ digital twins are qualified by the European Medicines Agency and align with current FDA guidance.
Company: Unlearn.ai, Inc.
Round: Series C
Funding Month: February 2024
Lead Investors: Altimeter Capital
Additional Investors: Radical Ventures, Wittington Ventures, Mubadala Capital, Epic Ventures, and Necessary Venture Capital
Company Website: https://www.unlearn.ai/
Software Category: Clinical Trial